Literature DB >> 20144296

Oral insulin: the rationale for this approach and current developments.

Ehud Arbit1, Miriam Kidron.   

Abstract

Insulin remains the most effective and durable hypoglycemic agent for the treatment of diabetes. The addition of an effective oral insulin dosage form to the antidiabetes armamentarium may have significant benefits in terms of fostering compliance and adherence among patients, as well as physiologic advantages due to the fact that such a dosage form replicates the natural route of insulin secretion and absorption through the portal vein and targets the liver directly. Several companies have developed technological platforms that protect polypeptides and proteins from enzymatic hydrolysis, enable their transport across the epithelial lining, and promote their absorption from the gastrointestinal tract. A review of the potential physiological rationale and advantages, as well as of current pertinent technologies used specifically with insulin, is herewith provided. 2009 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20144296      PMCID: PMC2769870          DOI: 10.1177/193229680900300322

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  33 in total

Review 1.  Physiological consequences of phasic insulin release in the normal animal.

Authors:  Alan D Cherrington; Dana Sindelar; Dale Edgerton; Kurt Steiner; Owen P McGuinness
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

2.  Direct and indirect effects of insulin on glucose uptake and storage by the liver.

Authors:  Shosuke Satake; Mary Courtney Moore; Kayano Igawa; Margaret Converse; Benjamin Farmer; Doss W Neal; Alan D Cherrington
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

3.  Process and purification for manufacture of a modified insulin intended for oral delivery.

Authors:  Nitesh Dave; Partha Hazra; Anand Khedkar; H S Manjunath; Harish Iyer; Shrikumar Suryanarayanan
Journal:  J Chromatogr A       Date:  2007-07-22       Impact factor: 4.759

4.  {beta}-Cell function following human islet transplantation for type 1 diabetes.

Authors:  Michael R Rickels; Mark H Schutta; James F Markmann; Clyde F Barker; Ali Naji; Karen L Teff
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

5.  Assessment of hepatic insulin action in obese type 2 diabetic patients.

Authors:  P Staehr; O Hother-Nielsen; K Levin; J J Holst; H Beck-Nielsen
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

Review 6.  Insulin and cancer (Review).

Authors:  J M Argilés; F J López-Soriano
Journal:  Int J Oncol       Date:  2001-04       Impact factor: 5.650

7.  Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database.

Authors:  Enzo Bonora; Brunella Capaldo; Paolo Cavallo Perin; Stefano Del Prato; Giancarlo De Mattia; Lucia Frittitta; Simona Frontoni; Frida Leonetti; Livio Luzi; Giulio Marchesini; Maria Adelaide Marini; Andrea Natali; Giuseppe Paolisso; Pier Marco Piatti; Arturo Pujia; Anna Solini; Roberto Vettor; Riccardo C Bonadonna
Journal:  Nutr Metab Cardiovasc Dis       Date:  2007-12-03       Impact factor: 4.222

8.  Suppression of endogenous glucose production by mild hyperinsulinemia during exercise is determined predominantly by portal venous insulin.

Authors:  Raul C Camacho; R Richard Pencek; D Brooks Lacy; Freyja D James; David H Wasserman
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

9.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation.

Authors:  Edmond A Ryan; Tami Shandro; Kristy Green; Breay W Paty; Peter A Senior; David Bigam; A M James Shapiro; Marie-Christine Vantyghem
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

10.  Insulin resistance and hyperinsulinemia: you can't have one without the other.

Authors:  Sun H Kim; Gerald M Reaven
Journal:  Diabetes Care       Date:  2008-07       Impact factor: 19.112

View more
  23 in total

Review 1.  Absorption enhancers: applications and advances.

Authors:  Bruce J Aungst
Journal:  AAPS J       Date:  2011-11-22       Impact factor: 4.009

Review 2.  Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation.

Authors:  W Blair Geho; Hans C Geho; John R Lau; Theophilus J Gana
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

3.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

Review 4.  Oral Hypoglycemic Agents in pregnancy: An Update.

Authors:  Nagandla Kavitha; Somsubhra De; Sachchithanantham Kanagasabai
Journal:  J Obstet Gynaecol India       Date:  2013-03-27

5.  Intraintestinal and Parenteral Administration of an Insulin Analogue Leads to Comparable Activation of Signaling Downstream of the Insulin Receptor in the Small Intestine.

Authors:  Henning Hvid; Jonas Kildegaard; Kim Kristensen; Trine Porsgaard; Mikkel S Jørgensen; Borja Ballarín-González; Jonas Ahnfelt-Rønne; Bo F Hansen; Erica Nishimura
Journal:  J Diabetes Sci Technol       Date:  2019-06-12

6.  Chemically Precise Glycoengineering Improves Human Insulin.

Authors:  Xiaoyang Guan; Patrick K Chaffey; Xiuli Wei; Daniel R Gulbranson; Yuan Ruan; Xinfeng Wang; Yaohao Li; Yan Ouyang; Liqun Chen; Chen Zeng; Theo N Koelsch; Amy H Tran; Wei Liang; Jingshi Shen; Zhongping Tan
Journal:  ACS Chem Biol       Date:  2017-12-01       Impact factor: 5.100

7.  Insulin therapies: Current and future trends at dawn.

Authors:  Subhashini Yaturu
Journal:  World J Diabetes       Date:  2013-02-15

8.  A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus.

Authors:  W Blair Geho; Len N Rosenberg; Sherwyn L Schwartz; John R Lau; Theophilus J Gana
Journal:  J Diabetes Sci Technol       Date:  2014-02-27

9.  Diabetes mellitus: new challenges and innovative therapies.

Authors:  Cristina M Sena; Carla F Bento; Paulo Pereira; Raquel Seiça
Journal:  EPMA J       Date:  2010-03-13       Impact factor: 6.543

10.  Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study.

Authors:  Roy Eldor; Ehud Arbit; Asher Corcos; Miriam Kidron
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.